find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at 201-518-3587, or email us.
60
Clinical Trials
Lymphoma
NA
Active
nct/study# NCT04981795 / MOR208C414
Prospective Multicenter Observational Study Of Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma Starting Second- Or Third-Line Therapy And Not Receiving Autologous Stem Cell Transplant (REAL-MIND)
Learn More
Lymphoma
Phase I/II
Accepting Patients
nct/study# NCT02628405 / RU051417I
Phase I/II, Open-Label Study Of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) With Lenalidomide-R-ICE (R2-ICE) In Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Learn More
Lymphoma
NA
Accepting Patients
nct/study# NA / 2021-0328
Patient Characteristics And Outcomes In Lymphoma With Pre-Existing Autoimmune Diseases.
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT04231747 / CC-97540-NHL-001
A Phase 1, Multicenter, Open-Label Study Of CC-97540, CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, In Subjects With Relapsed Or Refractory B-Cell Non-Hodgkin Lymphoma
Learn More
Lymphoma
Phase II
Accepting Patients
nct/study# NCT03646123 / SGN35-027
Multiple Part Clinical Trial Of Brentuximab Vedotin In Classical Hodgkin Lymphoma Subjects
Learn More
Lymphoma
Phase I
Accepting Patients
nct/study# NCT03930953 / CC-99282-NHL-001
A Phase 1, Multi-Center, Open-Label Study To Assess The Safety, Pharmacokinetics, And Preliminary Efficacy Of An Orally Available Small Molecule, CC-99282, Alone And In Combination With Rituximab In Subjects With Relapsed Or Refractory Non-Hodgkin Lymphomas (R/R NHL)
Learn Morewe are here for you
For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.